Symbols / OPK $1.20 +5.26% OPKO Health, Inc.
OPK Chart
About
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 921.24M |
| Enterprise Value | 897.71M | Income | -225.68M | Sales | 606.88M |
| Book/sh | 1.67 | Cash/sh | 0.48 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2275 | IPO | — |
| P/E | — | Forward P/E | -3.64 | PEG | — |
| P/S | 1.52 | P/B | 0.72 | P/C | — |
| EV/EBITDA | -7.05 | EV/Sales | 1.48 | Quick Ratio | 3.21 |
| Current Ratio | 3.97 | Debt/Eq | 31.29 | LT Debt/Eq | — |
| EPS (ttm) | -0.30 | EPS next Y | -0.33 | EPS Growth | — |
| Revenue Growth | -19.20% | Earnings | 2026-04-30 | ROA | -6.62% |
| ROE | -17.14% | ROIC | — | Gross Margin | 13.50% |
| Oper. Margin | -28.98% | Profit Margin | -37.19% | Shs Outstand | 759.07M |
| Shs Float | 339.45M | Short Float | 7.60% | Short Ratio | 15.86 |
| Short Interest | — | 52W High | 1.60 | 52W Low | 1.10 |
| Beta | 1.49 | Avg Volume | 2.76M | Volume | 1.94M |
| Target Price | $3.40 | Recom | None | Prev Close | $1.14 |
| Price | $1.20 | Change | 5.26% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-02 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-11-20 | init | JP Morgan | — → Neutral | — |
| 2025-10-31 | down | Jefferies | Buy → Hold | $2 |
| 2025-10-30 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-05-01 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-04-25 | init | JP Morgan | — → Neutral | — |
| 2025-04-07 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-12 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-03-12 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-02-28 | main | Barrington Research | Outperform → Outperform | $2 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-11-08 | main | Barrington Research | Outperform → Outperform | $2 |
| 2024-09-26 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-20 | main | Barrington Research | Outperform → Outperform | $2 |
| 2024-09-17 | reit | Piper Sandler | Overweight → Overweight | $3 |
| 2024-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-08 | main | Barrington Research | Outperform → Outperform | $2 |
| 2024-07-18 | main | Piper Sandler | Overweight → Overweight | $3 |
News
RSS: Latest OPK news- Here's Why You Should Hold OPK Stock in Your Portfolio for Now - Yahoo Finance hu, 19 Mar 2026 07
- Insider Purchase: CEO & Chairman of $OPK Buys 155,496 Shares | OPK Stock News - Quiver Quantitative Wed, 19 Nov 2025 08
- OPKO Health, Inc.'s (NASDAQ:OPK) Share Price Not Quite Adding Up - simplywall.st Fri, 19 Sep 2025 07
- OPKO Health inks $1B-plus Regeneron antibody pact in Q4 update - Stock Titan hu, 26 Feb 2026 08
- Opko Health CEO Phillip Frost buys $737,747 in OPK stock - Investing.com ue, 18 Nov 2025 08
- OPK May 2026 5.000 call (OPK260515C00005000) stock price, news, quote and history - Yahoo Finance Singapore Mon, 06 Apr 2026 05
- Opko Health (OPK) director adds 10,000 shares in open-market buy - Stock Titan Fri, 20 Mar 2026 07
- OPKO Health (NASDAQ:OPK investor five-year losses grow to 58% as the stock sheds US$64m this past week - Yahoo Finance ue, 28 Oct 2025 07
- OPKO Health (NASDAQ: OPK) director reports initial common stock holdings - Stock Titan Fri, 20 Mar 2026 07
- OPK May 2026 1.000 put (OPK260515P00001000) Interactive Stock Chart - ca.finance.yahoo.com Fri, 03 Apr 2026 19
- OPKO Health (NASDAQ: OPK) director granted 50,000 options at $1.17 - Stock Titan Fri, 20 Mar 2026 07
- OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands - Yahoo Finance Fri, 01 Aug 2025 07
- Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now - Yahoo Finance ue, 09 Dec 2025 08
- The Bull Case For OPKO Health (OPK) Could Change Following CEO Frost's Major Share Purchase Amid Downgrade - Yahoo Finance hu, 20 Nov 2025 08
- OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance hu, 26 Feb 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
606.88
-14.90%
|
713.14
-17.41%
|
863.50
-14.01%
|
1,004.20
|
| Operating Revenue |
|
606.88
-14.90%
|
713.14
-17.41%
|
863.50
-14.01%
|
1,004.20
|
| Cost Of Revenue |
|
400.94
-18.94%
|
494.63
-9.30%
|
545.37
-23.83%
|
715.98
|
| Reconciled Cost Of Revenue |
|
387.20
-19.18%
|
479.09
-8.94%
|
526.10
-24.31%
|
695.11
|
| Gross Profit |
|
205.94
-5.75%
|
218.51
-31.31%
|
318.13
+10.38%
|
288.22
|
| Operating Expense |
|
424.93
-13.65%
|
492.07
+3.34%
|
476.18
-10.88%
|
534.34
|
| Research And Development |
|
124.03
+17.89%
|
105.21
+17.44%
|
89.59
+21.26%
|
73.89
|
| Selling General And Administration |
|
223.00
-26.70%
|
304.22
+1.22%
|
300.56
-19.35%
|
372.67
|
| Total Expenses |
|
825.86
-16.30%
|
986.70
-3.41%
|
1,021.55
-18.30%
|
1,250.32
|
| Operating Income |
|
-218.99
+19.95%
|
-273.56
-73.08%
|
-158.06
+35.78%
|
-246.12
|
| Total Operating Income As Reported |
|
-117.41
+22.79%
|
-152.06
+3.16%
|
-157.02
+30.60%
|
-226.25
|
| EBITDA |
|
-41.27
-130.51%
|
135.28
+306.48%
|
-65.52
+75.81%
|
-270.81
|
| Normalized EBITDA |
|
-142.42
-456.53%
|
39.95
+160.74%
|
-65.77
+77.42%
|
-291.33
|
| Reconciled Depreciation |
|
91.63
-6.67%
|
98.18
-6.76%
|
105.30
-3.09%
|
108.66
|
| EBIT |
|
-132.90
-458.20%
|
37.10
+121.72%
|
-170.81
+54.99%
|
-379.46
|
| Total Unusual Items |
|
101.15
+6.10%
|
95.33
+37285.10%
|
0.26
-98.76%
|
20.52
|
| Total Unusual Items Excluding Goodwill |
|
101.15
+6.10%
|
95.33
+37285.10%
|
0.26
-98.76%
|
20.52
|
| Special Income Charges |
|
101.58
-16.39%
|
121.49
+11627.12%
|
1.04
-94.79%
|
19.87
|
| Restructuring And Mergern Acquisition |
|
0.00
|
0.00
+100.00%
|
-1.04
+21.04%
|
-1.31
|
| Write Off |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-225.68
-324.02%
|
-53.22
+71.82%
|
-188.86
+42.49%
|
-328.40
|
| Pretax Income |
|
-241.36
-2229.32%
|
-10.36
+94.38%
|
-184.32
+52.92%
|
-391.52
|
| Net Non Operating Interest Income Expense |
|
-93.65
-139.89%
|
-39.04
-309.94%
|
-9.52
+5.48%
|
-10.07
|
| Interest Expense Non Operating |
|
108.46
+128.51%
|
47.47
+251.44%
|
13.51
+12.03%
|
12.06
|
| Net Interest Income |
|
-93.65
-139.89%
|
-39.04
-309.94%
|
-9.52
+5.48%
|
-10.07
|
| Interest Expense |
|
108.46
+128.51%
|
47.47
+251.44%
|
13.51
+12.03%
|
12.06
|
| Interest Income Non Operating |
|
14.81
+75.78%
|
8.43
+111.55%
|
3.98
+101.06%
|
1.98
|
| Interest Income |
|
14.81
+75.78%
|
8.43
+111.55%
|
3.98
+101.06%
|
1.98
|
| Other Income Expense |
|
71.27
-76.42%
|
302.24
+1905.57%
|
-16.74
+87.63%
|
-135.32
|
| Other Non Operating Income Expenses |
|
-29.88
-114.44%
|
206.90
+1317.51%
|
-16.99
+89.10%
|
-155.84
|
| Gain On Sale Of Security |
|
-0.43
+98.36%
|
-26.16
-3249.68%
|
-0.78
-220.34%
|
0.65
|
| Tax Provision |
|
-15.71
-136.67%
|
42.84
+865.61%
|
4.44
+106.99%
|
-63.50
|
| Tax Rate For Calcs |
|
0.00
-69.00%
|
0.00
+0.00%
|
0.00
+29.63%
|
0.00
|
| Tax Effect Of Unusual Items |
|
6.58
-67.11%
|
20.02
+37285.10%
|
0.05
-98.39%
|
3.32
|
| Net Income Including Noncontrolling Interests |
|
-225.68
-324.02%
|
-53.22
+71.82%
|
-188.86
+42.49%
|
-328.40
|
| Net Income From Continuing Operation Net Minority Interest |
|
-225.68
-324.02%
|
-53.22
+71.82%
|
-188.86
+42.49%
|
-328.40
|
| Net Income From Continuing And Discontinued Operation |
|
-225.68
-324.02%
|
-53.22
+71.82%
|
-188.86
+42.49%
|
-328.40
|
| Net Income Continuous Operations |
|
-225.68
-324.02%
|
-53.22
+71.82%
|
-188.86
+42.49%
|
-328.40
|
| Normalized Income |
|
-320.24
-149.15%
|
-128.54
+32.01%
|
-189.06
+45.29%
|
-345.60
|
| Net Income Common Stockholders |
|
-225.68
-324.02%
|
-53.22
+71.82%
|
-188.86
+42.49%
|
-328.40
|
| Diluted EPS |
|
-0.30
-275.00%
|
-0.08
+68.00%
|
-0.25
+45.65%
|
-0.46
|
| Basic EPS |
|
-0.30
-275.00%
|
-0.08
+68.00%
|
-0.25
+45.65%
|
-0.46
|
| Basic Average Shares |
|
751.13
+8.23%
|
694.02
-7.68%
|
751.72
+4.54%
|
719.06
|
| Diluted Average Shares |
|
751.13
+8.23%
|
694.02
-7.68%
|
751.72
+4.54%
|
719.06
|
| Diluted NI Availto Com Stockholders |
|
-225.68
-324.02%
|
-53.22
+71.82%
|
-188.86
+42.49%
|
-328.40
|
| Amortization |
|
77.89
-5.74%
|
82.63
-3.95%
|
86.03
-2.00%
|
87.78
|
| Amortization Of Intangibles Income Statement |
|
77.89
-5.74%
|
82.63
-3.95%
|
86.03
-2.00%
|
87.78
|
| Depreciation Amortization Depletion Income Statement |
|
77.89
-5.74%
|
82.63
-3.95%
|
86.03
-2.00%
|
87.78
|
| Depreciation And Amortization In Income Statement |
|
77.89
-5.74%
|
82.63
-3.95%
|
86.03
-2.00%
|
87.78
|
| Earnings From Equity Interest Net Of Tax |
|
-0.03
-61.11%
|
-0.02
+83.18%
|
-0.11
+72.06%
|
-0.38
|
| Gain On Sale Of PPE |
|
101.58
-16.39%
|
121.49
|
0.00
-100.00%
|
18.56
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,931.94
-12.19%
|
2,200.21
+9.37%
|
2,011.70
-7.18%
|
2,167.26
|
| Current Assets |
|
581.88
-12.11%
|
662.09
+113.94%
|
309.48
-21.56%
|
394.52
|
| Cash Cash Equivalents And Short Term Investments |
|
369.07
-14.55%
|
431.94
+350.49%
|
95.88
-37.41%
|
153.19
|
| Cash And Cash Equivalents |
|
369.07
-14.55%
|
431.94
+350.49%
|
95.88
-37.41%
|
153.19
|
| Receivables |
|
126.12
-17.05%
|
152.05
+16.78%
|
130.20
-12.39%
|
148.61
|
| Accounts Receivable |
|
90.25
-23.52%
|
118.02
-4.35%
|
123.38
-3.09%
|
127.31
|
| Gross Accounts Receivable |
|
92.33
-22.60%
|
119.28
-4.86%
|
125.38
-4.64%
|
131.47
|
| Allowance For Doubtful Accounts Receivable |
|
-2.07
-63.38%
|
-1.27
+36.65%
|
-2.00
+51.95%
|
-4.16
|
| Other Receivables |
|
24.02
-6.77%
|
25.77
+887.16%
|
2.61
-80.08%
|
13.11
|
| Taxes Receivable |
|
11.84
+43.26%
|
8.27
+96.30%
|
4.21
-48.59%
|
8.19
|
| Inventory |
|
65.82
+15.89%
|
56.80
-13.55%
|
65.70
-11.29%
|
74.06
|
| Raw Materials |
|
24.62
-1.15%
|
24.91
-28.52%
|
34.84
-8.41%
|
38.05
|
| Work In Process |
|
0.73
-69.17%
|
2.35
+36.05%
|
1.73
-29.32%
|
2.45
|
| Finished Goods |
|
43.99
+36.16%
|
32.31
-9.20%
|
35.58
-4.19%
|
37.14
|
| Prepaid Assets |
|
12.70
+19.77%
|
10.60
+5.77%
|
10.03
-19.24%
|
12.41
|
| Assets Held For Sale Current |
|
—
|
—
|
—
|
0.00
|
| Other Current Assets |
|
8.17
-23.70%
|
10.71
+39.52%
|
7.67
+22.73%
|
6.25
|
| Total Non Current Assets |
|
1,350.06
-12.23%
|
1,538.12
-9.64%
|
1,702.22
-3.98%
|
1,772.73
|
| Net PPE |
|
120.86
-2.64%
|
124.14
-13.50%
|
143.52
+18.02%
|
121.60
|
| Gross PPE |
|
246.47
-6.23%
|
262.84
-12.58%
|
300.64
+13.88%
|
264.01
|
| Accumulated Depreciation |
|
-125.62
+9.43%
|
-138.70
+11.73%
|
-157.13
-10.34%
|
-142.41
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
2.54
+13.36%
|
2.24
-7.71%
|
2.42
+4.66%
|
2.32
|
| Buildings And Improvements |
|
15.57
+19.17%
|
13.06
-30.83%
|
18.89
+3.12%
|
18.31
|
| Machinery Furniture Equipment |
|
139.44
-9.08%
|
153.36
-13.81%
|
177.93
+2.06%
|
174.34
|
| Construction In Progress |
|
27.65
+43.78%
|
19.23
+265.90%
|
5.25
+9.64%
|
4.79
|
| Other Properties |
|
46.93
-13.10%
|
54.00
-20.69%
|
68.09
+75.82%
|
38.73
|
| Leases |
|
14.35
-31.46%
|
20.94
-25.36%
|
28.06
+9.96%
|
25.52
|
| Goodwill And Other Intangible Assets |
|
1,195.57
-10.84%
|
1,340.87
-12.56%
|
1,533.54
-5.01%
|
1,614.37
|
| Goodwill |
|
484.29
-8.50%
|
529.25
-11.53%
|
598.26
+0.40%
|
595.85
|
| Other Intangible Assets |
|
711.28
-12.36%
|
811.61
-13.22%
|
935.28
-8.17%
|
1,018.52
|
| Investments And Advances |
|
14.16
-74.05%
|
54.58
+239.43%
|
16.08
-42.68%
|
28.05
|
| Long Term Equity Investment |
|
0.76
-3.68%
|
0.79
-92.56%
|
10.58
-51.95%
|
22.02
|
| Other Non Current Assets |
|
19.47
+5.05%
|
18.54
+104.15%
|
9.08
+4.62%
|
8.68
|
| Total Liabilities Net Minority Interest |
|
663.99
-20.46%
|
834.76
+34.10%
|
622.48
+2.79%
|
605.61
|
| Current Liabilities |
|
146.68
-24.04%
|
193.10
-3.48%
|
200.05
-6.29%
|
213.48
|
| Payables And Accrued Expenses |
|
84.14
-31.40%
|
122.66
+3.46%
|
118.56
-2.98%
|
122.21
|
| Payables |
|
44.70
-35.54%
|
69.35
-2.41%
|
71.06
-1.77%
|
72.34
|
| Accounts Payable |
|
41.10
-12.68%
|
47.07
-32.44%
|
69.68
+4.01%
|
66.99
|
| Current Accrued Expenses |
|
39.45
-26.01%
|
53.32
+12.24%
|
47.50
-4.74%
|
49.87
|
| Employee Benefits |
|
5.54
-61.17%
|
14.27
|
0.00
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
33.78
-1.14%
|
34.17
+18.01%
|
28.95
-14.25%
|
33.77
|
| Total Tax Payable |
|
3.60
-83.86%
|
22.27
+1509.47%
|
1.38
-74.14%
|
5.35
|
| Current Debt And Capital Lease Obligation |
|
22.86
-22.11%
|
29.35
-31.93%
|
43.12
-15.50%
|
51.03
|
| Current Debt |
|
10.25
-31.75%
|
15.02
-44.97%
|
27.29
-25.41%
|
36.59
|
| Other Current Borrowings |
|
10.25
-31.75%
|
15.02
-44.97%
|
27.29
-25.41%
|
36.59
|
| Current Capital Lease Obligation |
|
12.61
-12.01%
|
14.33
-9.45%
|
15.82
+9.60%
|
14.44
|
| Current Deferred Liabilities |
|
—
|
—
|
0.00
|
0.00
|
| Current Deferred Revenue |
|
—
|
—
|
0.00
|
0.00
|
| Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
517.31
-19.38%
|
641.67
+51.90%
|
422.43
+7.73%
|
392.13
|
| Long Term Debt And Capital Lease Obligation |
|
373.92
-21.30%
|
475.10
+67.61%
|
283.45
+11.37%
|
254.52
|
| Long Term Debt |
|
333.71
-20.96%
|
422.18
+90.14%
|
222.03
+1.17%
|
219.47
|
| Long Term Capital Lease Obligation |
|
40.21
-24.01%
|
52.91
-13.84%
|
61.41
+75.21%
|
35.05
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
5.54
-61.17%
|
14.27
|
0.00
|
—
|
| Non Current Deferred Liabilities |
|
126.24
-10.34%
|
140.80
+11.06%
|
126.78
+0.17%
|
126.56
|
| Non Current Deferred Revenue |
|
—
|
0.01
-14.29%
|
0.01
-94.93%
|
0.14
|
| Non Current Deferred Taxes Liabilities |
|
126.24
-10.34%
|
140.80
+11.06%
|
126.77
+0.27%
|
126.43
|
| Other Non Current Liabilities |
|
11.60
+0.87%
|
11.50
-5.71%
|
12.20
+10.44%
|
11.05
|
| Stockholders Equity |
|
1,267.96
-7.14%
|
1,365.45
-1.71%
|
1,389.22
-11.04%
|
1,561.65
|
| Common Stock Equity |
|
1,267.96
-7.14%
|
1,365.45
-1.71%
|
1,389.22
-11.04%
|
1,561.65
|
| Capital Stock |
|
7.90
+12.62%
|
7.01
-10.29%
|
7.82
+0.09%
|
7.81
|
| Common Stock |
|
7.90
+12.62%
|
7.01
-10.29%
|
7.82
+0.09%
|
7.81
|
| Share Issued |
|
789.92
+12.63%
|
701.35
-10.31%
|
781.94
+0.08%
|
781.31
|
| Ordinary Shares Number |
|
759.07
+13.03%
|
671.55
-13.16%
|
773.28
+0.08%
|
772.65
|
| Treasury Shares Number |
|
30.85
+3.52%
|
29.80
+244.31%
|
8.66
+0.00%
|
8.66
|
| Additional Paid In Capital |
|
3,574.94
+2.69%
|
3,481.36
+1.41%
|
3,433.01
+0.33%
|
3,421.87
|
| Retained Earnings |
|
-2,290.69
-10.93%
|
-2,065.01
-2.65%
|
-2,011.79
-10.36%
|
-1,822.92
|
| Gains Losses Not Affecting Retained Earnings |
|
-21.02
+62.56%
|
-56.13
-47.59%
|
-38.03
+12.22%
|
-43.32
|
| Treasury Stock |
|
3.18
+77.33%
|
1.79
+0.00%
|
1.79
+0.00%
|
1.79
|
| Other Equity Adjustments |
|
-21.02
+62.56%
|
-56.13
-47.59%
|
-38.03
+12.22%
|
-43.32
|
| Total Equity Gross Minority Interest |
|
1,267.96
-7.14%
|
1,365.45
-1.71%
|
1,389.22
-11.04%
|
1,561.65
|
| Total Capitalization |
|
1,601.67
-10.40%
|
1,787.63
+10.95%
|
1,611.25
-9.54%
|
1,781.12
|
| Working Capital |
|
435.20
-7.20%
|
468.99
+328.60%
|
109.42
-39.56%
|
181.04
|
| Invested Capital |
|
1,611.92
-10.58%
|
1,802.65
+10.02%
|
1,638.55
-9.86%
|
1,817.71
|
| Total Debt |
|
396.78
-21.34%
|
504.44
+54.47%
|
326.56
+6.88%
|
305.55
|
| Net Debt |
|
—
|
5.27
-96.57%
|
153.45
+49.17%
|
102.87
|
| Capital Lease Obligations |
|
52.82
-21.45%
|
67.24
-12.94%
|
77.24
+56.07%
|
49.49
|
| Net Tangible Assets |
|
72.39
+194.49%
|
24.58
+117.03%
|
-144.32
-173.74%
|
-52.72
|
| Tangible Book Value |
|
72.39
+194.49%
|
24.58
+117.03%
|
-144.32
-173.74%
|
-52.72
|
| Available For Sale Securities |
|
13.41
-75.08%
|
53.79
+878.43%
|
5.50
-8.81%
|
6.03
|
| Current Provisions |
|
5.90
-14.78%
|
6.92
-26.54%
|
9.42
+45.44%
|
6.48
|
| Financial Assets |
|
0.00
+0.00%
|
0.00
+50.00%
|
0.00
-92.86%
|
0.03
|
| Interest Payable |
|
5.44
-34.57%
|
8.31
|
—
|
—
|
| Inventories Adjustments Allowances |
|
-3.52
-26.75%
|
-2.77
+57.07%
|
-6.46
-80.78%
|
-3.57
|
| Investmentin Financial Assets |
|
13.41
-75.08%
|
53.79
+878.43%
|
5.50
-8.81%
|
6.03
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-178.54
+2.70%
|
-183.49
-550.74%
|
-28.20
+70.38%
|
-95.19
|
| Cash Flow From Continuing Operating Activities |
|
-178.54
+2.70%
|
-183.49
-550.74%
|
-28.20
+70.38%
|
-95.19
|
| Net Income From Continuing Operations |
|
-225.68
-324.02%
|
-53.22
+71.82%
|
-188.86
+42.49%
|
-328.40
|
| Depreciation Amortization Depletion |
|
91.63
-6.67%
|
98.18
-6.76%
|
105.30
-3.09%
|
108.66
|
| Depreciation And Amortization |
|
91.63
-6.67%
|
98.18
-6.76%
|
105.30
-3.09%
|
108.66
|
| Other Non Cash Items |
|
71.49
+454.49%
|
12.89
+339.13%
|
2.94
+12.97%
|
2.60
|
| Stock Based Compensation |
|
10.71
-3.02%
|
11.05
-3.20%
|
11.41
-38.34%
|
18.51
|
| Asset Impairment Charge |
|
1.01
|
0.00
|
0.00
|
—
|
| Deferred Tax |
|
-15.00
-201.73%
|
14.74
+9998.63%
|
0.15
+100.20%
|
-74.41
|
| Deferred Income Tax |
|
-15.00
-201.73%
|
14.74
+9998.63%
|
0.15
+100.20%
|
-74.41
|
| Operating Gains Losses |
|
-72.14
+60.98%
|
-184.87
-13046.22%
|
1.43
+107.66%
|
-18.63
|
| Unrealized Gain Loss On Investment Securities |
|
0.62
+100.54%
|
-114.43
-748.43%
|
17.65
-88.53%
|
153.84
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
-3.25
+94.88%
|
-63.40
-4899.17%
|
1.32
+390.33%
|
-0.46
|
| Change In Working Capital |
|
-41.18
-227.99%
|
32.17
+47.60%
|
21.80
-48.89%
|
42.65
|
| Change In Receivables |
|
30.21
+13833.18%
|
-0.22
-106.45%
|
3.41
-97.35%
|
128.60
|
| Changes In Account Receivables |
|
30.21
+13833.18%
|
-0.22
-106.45%
|
3.41
-97.35%
|
128.60
|
| Change In Inventory |
|
-4.12
-197.65%
|
4.22
-72.25%
|
15.20
+11.24%
|
13.66
|
| Change In Payables And Accrued Expense |
|
-62.06
-321.46%
|
28.02
+1157.80%
|
-2.65
+97.36%
|
-100.50
|
| Change In Accrued Expense |
|
-47.84
-198.27%
|
48.68
+988.86%
|
-5.48
+93.99%
|
-91.11
|
| Change In Payable |
|
-14.22
+31.19%
|
-20.66
-830.62%
|
2.83
+130.12%
|
-9.39
|
| Change In Account Payable |
|
-14.22
+31.19%
|
-20.66
-830.62%
|
2.83
+130.12%
|
-9.39
|
| Change In Other Working Capital |
|
0.18
-95.43%
|
3.90
+476.35%
|
-1.04
-143.73%
|
2.37
|
| Change In Other Current Assets |
|
-5.40
-44.23%
|
-3.74
-154.42%
|
6.88
+564.28%
|
-1.48
|
| Investing Cash Flow |
|
230.30
-34.61%
|
352.21
+2035.45%
|
-18.20
-119.99%
|
91.04
|
| Cash Flow From Continuing Investing Activities |
|
230.30
-34.61%
|
352.21
+2035.45%
|
-18.20
-119.99%
|
91.04
|
| Net PPE Purchase And Sale |
|
0.29
+18.60%
|
0.24
-91.08%
|
2.71
+39.06%
|
1.95
|
| Sale Of PPE |
|
0.29
+18.60%
|
0.24
-91.08%
|
2.71
+39.06%
|
1.95
|
| Capital Expenditure |
|
-12.28
+50.91%
|
-25.01
-53.67%
|
-16.27
+33.78%
|
-24.58
|
| Capital Expenditure Reported |
|
-12.28
+50.91%
|
-25.01
-53.67%
|
-16.27
+33.78%
|
-24.58
|
| Net Investment Purchase And Sale |
|
52.18
-68.68%
|
166.60
+45670.33%
|
0.36
-99.68%
|
115.42
|
| Sale Of Investment |
|
52.18
-68.68%
|
166.60
+45670.33%
|
0.36
-99.68%
|
115.42
|
| Net Business Purchase And Sale |
|
190.10
-9.64%
|
210.38
+4307.56%
|
-5.00
-184.41%
|
-1.76
|
| Purchase Of Business |
|
-7.67
|
0.00
+100.00%
|
-5.00
-184.41%
|
-1.76
|
| Gain Loss On Sale Of Business |
|
—
|
—
|
0.00
+100.00%
|
-18.56
|
| Financing Cash Flow |
|
-118.06
-164.10%
|
184.17
+1729.36%
|
-11.30
-149.21%
|
22.97
|
| Cash Flow From Continuing Financing Activities |
|
-118.06
-164.10%
|
184.17
+1729.36%
|
-11.30
-149.21%
|
22.97
|
| Net Issuance Payments Of Debt |
|
-70.76
-124.57%
|
287.98
+2710.66%
|
-11.03
-146.46%
|
23.75
|
| Issuance Of Debt |
|
33.03
-96.48%
|
939.43
+39.86%
|
671.68
-36.61%
|
1,059.52
|
| Repayment Of Debt |
|
-103.79
+84.07%
|
-651.45
+4.58%
|
-682.71
+34.09%
|
-1,035.77
|
| Long Term Debt Issuance |
|
33.03
-96.48%
|
939.43
+39.86%
|
671.68
-36.61%
|
1,059.52
|
| Long Term Debt Payments |
|
-103.79
+84.07%
|
-651.45
+4.58%
|
-682.71
+34.09%
|
-1,035.77
|
| Net Long Term Debt Issuance |
|
-70.76
-124.57%
|
287.98
+2710.66%
|
-11.03
-146.46%
|
23.75
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
-47.04
+47.86%
|
-90.22
|
0.00
|
0.00
|
| Common Stock Payments |
|
-47.04
+47.86%
|
-90.22
|
0.00
|
0.00
|
| Repurchase Of Capital Stock |
|
-47.04
+47.86%
|
-90.22
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
-0.26
-23.08%
|
-0.21
+23.53%
|
-0.27
+64.86%
|
-0.77
|
| Net Other Financing Charges |
|
—
|
-13.38
|
—
|
—
|
| Changes In Cash |
|
-66.30
-118.79%
|
352.89
+711.62%
|
-57.70
-406.58%
|
18.82
|
| Effect Of Exchange Rate Changes |
|
3.43
+208.62%
|
-3.16
-913.66%
|
0.39
+214.45%
|
-0.34
|
| Beginning Cash Position |
|
445.62
+364.76%
|
95.88
-37.41%
|
153.19
+13.72%
|
134.71
|
| End Cash Position |
|
382.74
-14.11%
|
445.62
+364.76%
|
95.88
-37.41%
|
153.19
|
| Free Cash Flow |
|
-190.82
+8.48%
|
-208.50
-368.83%
|
-44.47
+62.87%
|
-119.77
|
| Interest Paid Supplemental Data |
|
37.94
+81.66%
|
20.88
+156.71%
|
8.13
+9.64%
|
7.42
|
| Income Tax Paid Supplemental Data |
|
24.46
+144.43%
|
10.01
+169.61%
|
3.71
-53.81%
|
8.04
|
| Common Stock Issuance |
|
—
|
—
|
—
|
—
|
| Earnings Losses From Equity Investments |
|
0.03
+61.11%
|
0.02
-83.18%
|
0.11
-72.06%
|
0.38
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
—
|
| Sale Of Business |
|
197.77
-5.99%
|
210.38
|
0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-20 View
- 42026-03-20 View
- 8-K2026-03-19 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42025-11-21 View
- 42025-11-20 View
- 42025-11-19 View
- 42025-11-18 View
- 42025-10-31 View
- 10-Q2025-10-29 View
- 8-K2025-10-29 View
- 8-K2025-09-15 View
- 42025-08-19 View
- 42025-08-08 View
- 10-Q2025-07-31 View
- 8-K2025-07-31 View
- 42025-05-29 View
- 42025-05-29 View
- 42025-05-29 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|